Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
Kevin L. Schwartz, Jun Wang, Mina Tadrous, et al.
Canadian Medical Association Journal (2023) Vol. 195, Iss. 6, pp. E220-E226
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Jennifer Hammond, Robert J. Fountaine, Carla Yunis, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1186-1195
Open Access | Times Cited: 59
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission
Liang En Wee, An Ting Tay, Calvin J. Chiew, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 10, pp. 1328-1333
Open Access | Times Cited: 26
Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
Colin R. Dormuth, Jason D. Kim, Anat Fisher, et al.
JAMA Network Open (2023) Vol. 6, Iss. 10, pp. e2336678-e2336678
Open Access | Times Cited: 25
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1502-1502
Open Access | Times Cited: 19
Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19
Jheng‐Yan Wu, Mei‐Yuan Liu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Open Access | Times Cited: 17
Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019–Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 6, pp. 805-815
Open Access | Times Cited: 16
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 112-112
Open Access | Times Cited: 5
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
Carlos Duarte, Michel L. Peters, Michelle H. M. de Goeij, et al.
Cost Effectiveness and Resource Allocation (2025) Vol. 23, Iss. 1
Open Access
Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
Ya‐Wen Tsai, Jheng‐Yan Wu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access | Times Cited: 13
Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023
Calvin Sjaarda, Lynette Lau, Jared T. Simpson, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2324963-e2324963
Open Access | Times Cited: 12
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Kathiaja Miranda Souza, G. Carrasco, Robin Rojas-Cortés, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0284006-e0284006
Open Access | Times Cited: 12
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
Jimena Pérez‐Vargas, Gabriel Lemieux, Connor A.H. Thompson, et al.
Antiviral Research (2024) Vol. 225, pp. 105869-105869
Open Access | Times Cited: 4
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 4
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Roopa Naik, Sreekant Avula, Sujith K Palleti, et al.
Cureus (2023)
Open Access | Times Cited: 11
Key Essentials during the Transition from the Acute Phase of the COVID-19 Pandemic
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
(2023)
Open Access | Times Cited: 10
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis
George N. Okoli, Nicole Askin, Rasheda Rabbani
The Annals of Family Medicine (2024) Vol. 22, Iss. 4, pp. 336-346
Open Access | Times Cited: 3
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances
José Luís Piñana, Ariadna Pérez, Pedro Chorão, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 8
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2)
Isolde Sommer, Dominic Ledinger, Kylie Thaler, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 10, pp. 1377-1385
Open Access | Times Cited: 8
Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis
Wan‐Hsuan Hsu, Bo-Wen Shiau, Tinghui Liu, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 10, pp. 1143-1151
Closed Access | Times Cited: 8
Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
Jin Ju Park, Hyunji Kim, Yong Kyun Kim, et al.
Journal of Korean Medical Science (2023) Vol. 38, Iss. 42
Open Access | Times Cited: 8
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 2
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Lei Yan, David Bui, Yuli Li, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 2
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
Courtney E. Harris, Abi Vijenthira, Shin Yeu Ong, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Closed Access | Times Cited: 7
COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina
Heather Henderson, David A. Wohl, William A. Fischer, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 4, pp. 859-867
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top